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Abstract
Introduction: In 2014, city leaders from around the world endorsed the Paris Declaration on Fast-Track Cities, pledging to
achieve the 2020 and 2030 HIV targets championed by UNAIDS. The City of Johannesburg – one of South Africa’s metropoli-
tan municipalities and also a health district – has over 600,000 people living with HIV (PLHIV), more than any other city
worldwide. We estimate what it would take in terms of programmatic targets and costs for the City of Johannesburg to meet
the Fast-Track targets, and demonstrate the impact that this would have.
Methods: We applied the Optima HIV epidemic and resource allocation model to demographic, epidemiological and beha-
vioural data on 26 sub-populations in Johannesburg. We used data on programme costs and coverage to produce baseline pro-
jections. We calculated how many people must be diagnosed, put onto treatment and maintained with viral suppression to
achieve the 2020 and 2030 targets. We also estimated how treatment needs – and therefore fiscal commitments – could be
reduced if the treatment targets are combined with primary HIV prevention interventions (voluntary medical male circumci-
sion (VMMC), an expanded condom programme, and comprehensive packages for female sex workers (FSW) and young
females).
Results: If current programmatic coverage were maintained, Johannesburg could expect 303,000 new infections and 96,000
AIDS-related deaths between 2017 and 2030 and 769,000 PLHIV by 2030. Achieving the Fast-Track targets would require an
additional 135,000 diagnoses and 232,000 people on treatment by 2020 (an increase in around 80% over 2016 treatment
numbers), but would avert 176,000 infections and 56,500 deaths by 2030. Assuming stable ART unit costs, this would require
ZAR 29 billion (USD 2.15 billion) in cumulative treatment investments over the 14 years to 2030. Plausible scale-ups of other
proven interventions (VMMC, condom distribution and FSW strategies) could yield additional reductions in new infections (be-
tween 4 and 15%), and in overall treatment investment needs. Scaling up VMMC in line with national targets is found to be
cost-effective in the medium term.
Conclusions: The scale-up in testing and treatment programmes over this decade has been rapid, but these efforts must be
doubled to reach 2020 targets. Strategic investments in proven interventions will help Johannesburg achieve the treatment
targets and be on track to end AIDS by 2030.
Keywords: Fast-Track targets; ending AIDS; Johannesburg; HIV modelling; allocative efficiency
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1 | INTRODUCTION
In 2014, city leaders from around the world endorsed the
Paris Declaration on Fast-Track Cities, pledging to achieve the
2020 and 2030 HIV targets championed by UNAIDS [1]. The
Fast-Track targets, now ubiquitous in the HIV field, state that
by 2020, 90% of all people living with HIV (PLHIV) will know
their HIV status, 90% of all people with diagnosed HIV infec-
tion will receive antiretroviral therapy (ART), and 90% of all
people receiving ART will be virally suppressed (90-90-90
targets), with these percentages increasing to 95% by 2030
(95-95-95 targets). The 90-90-90 and 95-95-95 targets are
associated with epidemiological milestones: approximately
80% to 90% reductions in new infections and AIDS-related
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deaths by 2030, often considered synonymous with the goal
of ending AIDS [2].
The City of Johannesburg became a signatory to the Paris
declaration in March 2016 along with 19 other municipalities
in South Africa, joining other cities around the world [3]. The
crucial role that cities will play in achieving the Fast-Track tar-
gets [4] is particularly relevant in South Africa; both Johannes-
burg and Durban metropolitan municipalities are estimated to
have more than 500,000 PLHIV, which would qualify them for
positions in the top 25 countries in the world according to
HIV burden if they were counted alongside nations (2013
UNAIDS estimates [5]; Figure 1). In this study, our focus is on
the City of Johannesburg.
Notwithstanding the considerable political will that Johan-
nesburg’s leaders demonstrated in signing the Paris Declara-
tion, it remains uncertain how to translate the Fast-Track
targets into programmatic or financial stratagems. The transla-
tion step calls for an analysis of the HIV care and treatment
cascade. Over the past 5 years, the HIV care and treatment
cascade has been established as a useful framework for
assessing the gaps in accessing the full range of diagnostic,
care and treatment services available for PLHIV [6-8]. Under-
standing and minimizing blockages and leakages along the cas-
cade is the only way that the Fast-Track targets can be
attained [9,10].
The HIV response within South Africa as a whole is heav-
ily focused on the achievement of the Fast-Track targets,
with many service delivery modalities in place to improve
diagnosis, linkage to and retention in care, and treatment
initiation, monitoring and adherence. Despite the recogni-
tion of the importance of cities in achieving the Fast-Track
targets, most studies tend to focus on analysing the care
and treatment cascade within countries [7,9,11-13] or
within clinics[14,15]. Aside from the strategic importance
of cities, an analysis of a city’s cascade can shed light on
how well the network of clinics is working together as a
whole. Mathematical models have proven useful in answer-
ing questions of this type, and a multitude of different
modelling frameworks have been developed in response,
both specifically for South Africa [16] and more generally
[17].
To understand what it will take for the City of Johannes-
burg to achieve the Fast-Track targets, we adapted the
Optima HIV epidemic and resource allocation model in order
to capture the key aspects of the HIV care and treatment
cascade [18]. Although the Optima HIV model has been suc-
cessfully applied in many countries to assess the impact and
optimize the allocation of HIV programme spending [19], it
has yet to be used for a detailed analysis of the care and
treatment cascade, largely due to a lack of comprehensive
data. For this analysis, we sought data from a number of
sources, including clinic-level data, cohort studies, national
reports, and a novel record-linkage analysis providing compre-
hensive viral load and CD4 data for Johannesburg. Using
these data in our specially tailored model, we estimate what it
would take in terms of programmatic targets and investments
for the City of Johannesburg to meet the Fast-Track targets,
and then estimate the epidemiological impact that this would
have.
2 | METHODS
2.1 | Model structure
We adapted the deterministic compartmental epidemic model
structure of Optima HIV [18], making several modifications in
order to better capture aspects of the care and treatment
cascade (Figure 2a). Each population group included in the
model has 37 possible health states: 7 treatment-related
states (susceptible, undiagnosed, diagnosed, in care, receiving
Figure 1. Estimated number of PLHIV in 2013 (UNAIDS [5]). Johannesburg and Durban have been disaggregated from the rest of South
Africa and are highlighted in pink. Together, the two cities make up 3% of the estimated global burden of HIV, with Johannesburg alone
accounting for around 9% of South Africa’s HIV burden.
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ART and not virally suppressed, receiving ART and virally
suppressed, lost-to-follow-up), with all infected stages further
disaggregated into 6 CD4-related states (acute HIV infection,
>500 cells/lL, 350 to 500 cells/lL, 200 to 350 cells/lL, 50
to 200 cells/lL, <50 cells/lL). In addition, we disaggregated
the total population of the City of Johannesburg (estimated
at 4.9 million in 2016) into 26 sub-populations: males and
females aged 15 to 60 stratified into 5-year age bands, plus
infants aged 0 to 2, children aged 3 to 14, males and females
aged 60+, female sex workers (FSW), clients of female sex
workers, men who have sex with men, and people who inject
drugs.
2.2 | Model transitions
The movement of people along the cascade is modelled by
the black arrows depicted in Figure 2a. Each arrow is associ-
ated with a probability of transitioning to a different stage of
the care continuum within a fixed interval of time, and each is
specific to a particular sub-population and CD4-related state.
Following the surveillance study undertaken by Howard
University in conjunction with the President’s Emergency Plan
For AIDS Relief (PEPFAR) and the National Department of
Health, we consider someone to be linked to care if they have
been enrolled in a facility for continuum of HIV care and have
(a)
(b)
Figure 2. (a) The compartmental structure of the Optima HIV epidemic model, adapted to account for the care and treatment cascade; (b)
Progress towards the Fast-Track targets over 2005–2016 (first 3 columns), and model estimates of the scale-up required to 2020 and 2030
(final 2 columns).
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completed and received the results of an initial ART eligibil-
ity assessment within 3 months of diagnosis [20]. The dif-
ferent transition probabilities associated with different CD4
counts are primarily intended to distinguish the behaviour
of people with <200 CD4 cells/lL (AIDS-stage infection)
and also capture differences in mortality rates. We assume
that people with AIDS-stage infection have a symptomatic
testing rate above the standard testing rate for their popu-
lation cohort, which gives us an estimated median CD4
count at diagnosis of 340 cells/lL in 2015, approximately
on par with other studies [21,22]. We assume that treat-
ment spots are first taken by those with lower CD4 counts,
which give us a mean CD4 count at time of treatment initi-
ation of 190 cells/ll, again comparable to other studies
[21]. In addition to the transitions along the cascade, we
also take into account transitions between different sub-
populations (for example, mixing between adult female and
FSW populations) and disease states (as stratified by CD4
counts).
2.3 | Data
The data used to inform the model’s transition probabilities
are summarized in Table 1. Details on the model equations
are provided in the Supplementary Material, and full details of
the model parameters are provided in the Optima HIV param-
eters sources compendium [23]. Estimating the current state
of the care and treatment cascade relied heavily on the
Howard University surveillance study [20].
2.4 | Model calibration
We initialized the model in 2000 and produced projections
from 2000 to 2030. We fitted the model to data on popula-
tion sizes, HIV prevalence and the number of people on ART
by adjusting a subset of the model’s parameters in order to
minimize the mean absolute percentage error between the
model’s estimates and the data, and then subjecting the pro-
jections produced by the model to scrutiny and validation by
the district, province and national health departments
involved in the study. For the purposes of fitting, we speci-
fied which of the model’s parameters could be adjusted, as it
is neither feasible nor desirable to allow all parameters to
vary freely. Since our focus is on modelling the care and
treatment cascade, we selected parameters to match the
cascade transitions depicted in Figure 1. Specifically, we fit-
ted: [1] the initial HIV prevalence in each sub-population; [2]
parameters controlling the probability of infection; [3] test-
ing rates (within 10% of reported values); [4] the percentage
of people linked to care within 3 months (within 10% of
reported values); [5] the average time taken from treatment
initiation to viral suppression, within the ranges given in
Table 1; [6] the proportion of people virally suppressed at
their last test (within 10% of reported values); [7] the pro-
portion of people not returning to their clinic after 90 days
and [8] all CD4 progression and recovery rates, within the
ranges given in Table 1. The key outputs of the calibration
are included in the Supplementary Material. The model’s
estimates of prevalence, infections, deaths, number of peo-
ple on ART and PLHIV are generally aligned to available
data.
2.5 | Model analysis
We estimated the HIV testing and treatment scale-up
required to meet the Fast-Track targets under a range of
assumptions about coverage levels of other programmes. As
the baseline scenario, we assume that coverage of all other
programmes would remain at latest reported levels. The test-
ing and treatment scale-up required under this baseline sce-
nario is shown in Figure 2b. We then constructed alternative
scenarios to describe plausible programmatic scale-ups,
informed by South Africa’s National Strategic Plan (NSP) for
2017 to 2022 [24] and the South African National Sex
Worker HIV Plan for 2016 to 2019 [25].
In modelling the impact of the 2017 to 2022 NSP, we
restrict our attention to Goal 1 (of a total 8 goals), which aims
to reduce new HIV infections through combination prevention
interventions, and more specifically to sub-objective 1.1.2, the
component of Goal 1 that outlines an approach for the provi-
sion of targeted biomedical HIV prevention services. (Sub-
objectives 1.1.1 and 1.1.3 relate to education programming,
which is outside of the scope of our modelling framework;
sub-objective 1.1.4 relates to the provision of PrEP, which we
model separately as part of the National Sex Worker Plan;
and sub-objective 1.1.5 relates to PMTCT, which we include
in the treatment scale-ups associated with the Fast-Track tar-
gets.) We omit Goal 2 because it relates to the attainment of
the Fast-Track targets (which we already model separately).
We omit Goal 3, which aims to reach all key and vulnerable
populations with customized and targeted interventions,
because concrete targets are yet to be formulated for many
of the indicators in the NSP’s Monitoring and Evaluation
Framework. Finally, we omit Goals 4–8 because these relate
to addressing the social and structural drivers of the epi-
demics, grounding the responses in a human rights approach,
promoting leadership, mobilizing resources and strengthening
strategic information, and while these are essential compo-
nents of the strategy, our modelling framework is best suited
to analysing the impact of biomedical and behavioural inter-
ventions designed to directly impact on one of the proximal
determinants of HIV transmission or mortality.
For each scenario, we calculated the coverage and esti-
mated investment levels required to attain the Fast-Track tar-
gets, as well as the impact.
3 | RESULTS
3.1 | Progress towards Fast-Track targets
We estimate that in 2016 there were 616,000 PLHIV in
Johannesburg, with 73% aware of their status, 77% of those
diagnosed linked to care (with 57% of newly diagnosed people
linked to care within 3 months), 80% of those who were ini-
tially linked to care retained in care (84% of whom are receiv-
ing treatment) and 54% of those receiving treatment with
viral suppression. Using the UNAIDS cascade with PLHIV as
denominator (which translates the Fast-Track targets to 90%-
81%-72%), the achievement of the three 90s in 2016 was
73%-48%-26%. The care and treatment cascade improved sig-
nificantly over the past 11 years across all stages for which
we have data (Figure 2b). The proportion of people aware of
their status was estimated to increase from 50% to 73%,
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Table 1. Key parameters used to inform the transitions for the epidemiological model.
Transitions Data types Data availability Value
Cascade
Infection Sexual behavioural data (number of acts per year &
probability of condom use with regular, casual
and commercial partners)
National Time-varying & population-specific
Injecting behavioural data (number of injections
per year & probability of syringe sharing)
National Time-varying & population-specific
Intervention uptake (% of people accessing
PrEP, circumcision, ART, OST & PMTCT)
Municipal Time-varying & population-specific
Per-act transmission probabilities Literature See Supplementary Materials
Efficacy of interventions Literature See Supplementary Materials
Partnership formation patterns National Time-varying & population-specific
Diagnosis % of population tested for HIV in the last 12 months National Time-varying & population-specific
Linkage to care % of people linked to care within 3 months of diagnosis Municipal Time-varying & population-specific
Treatment initiation Matched to available data on the number
of people on ART
Municipal Time-varying & population-specific
Viral suppression Average time taken from treatment initiation to viral
suppression; frequency of viral load monitoring
Municipal Time-varying
Treatment failure % of those who were virally suppressed
at their last VL test
Municipal Time-varying
Loss to follow-up % of people not returning to their clinic after 90 days Clinic Time-varying
CD4 change
CD4 progression Duration of acute infection [23] 0.24 [0.10, 0.30] years
Time to move from CD4 > 500 to 350 < CD4 < 500 [23] 0.95 [0.62, 1.16] years
Time to move from 350 < CD4 < 500 to
200 < CD4 < 350
[23] 3.00 [2.83, 3.16] years
Time to move from 200 < CD4 < 350 to 50 < CD4 < 200 [23] 3.74 [3.48, 4.00] years
Time to move from 50 < CD4 < 200 to CD4 < 50 [23] 1.50 [1.13, 2.25] years
CD4 recovery on
suppressive ART
Time to move from 350 < CD4 < 500 to CD4 > 500 [23] 2.20 [1.07, 7.28] years
Time to move from 200 < CD4 < 350 to
350 < CD4 < 500
[23] 1.42 [0.90, 3.42] years
Time to move from 50 < CD4 < 200 to 200 < CD4 < 350 [23] 2.14 [1.39, 3.58] years
Time to move from CD4 < 50 to 50 < CD4 < 200 [23] 0.66 [0.51, 0.94] years
Time from treatment initiation to achieve viral suppression [23] 0.20 [0.10, 0.30] years
CD4 progression &
recovery on
non-suppressive ART
% moving from CD4 > 500 to 350 < CD4 < 500 per year [23] 2.60 [0.50, 27.50]%
% moving from 350 < CD4 < 500 to CD4 > 500 per year [23] 15.00 [3.80, 88.50]%
% moving from 350 < CD4 < 500 to
200 < CD4 < 350 per year
[23] 10.00 [2.20, 87.00]%
% moving from 200 < CD4 < 350 to
350 < CD4 < 500 per year
[23] 5.30 [0.80, 82.70]%
% moving from 200 < CD4 < 350 to
50 < CD4 < 200 per year
[23] 16.20 [5.00, 86.90]%
% moving from 50 < CD4 < 200 to
200 < CD4 < 350 per year
[23] 11.70 [3.20, 68.60]%
% moving from 50 < CD4 < 200 to CD4 < 50 per year [23] 9.00 [1.90, 72.30]%
% moving from CD4 < 50 to 50 < CD4 < 200 per year [23] 11.10 [4.70, 56.30]%
Population transitions
Risk Average length of time spent as sex worker National 12 years
Average length of time spent as client of sex worker National 15 years
Age Defined by width of age bins N/A
The transitions between CD4 categories were determined following extensive literature review and data synthesis; full details are contained in
the Supplementary Materials. The transitions between cascade stages were informed by local data.
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attributable to significant increases in testing programme cov-
erage throughout the entire country [26]. In particular, the
proportion of MSM aware of their status was estimated to
increase from 30% to 63%, and in FSW the increase was even
more marked (from 30% to 70%, consistent with other esti-
mates [25,27]). Expanded treatment eligibility and major
investments in treatment increased the proportion of diag-
nosed people receiving treatment from 8% to 64% (although
treatment coverage remained low among FSW, at 23%
[26,27]).
3.2 | What will it take to achieve the Fast-Track
targets?
We estimate that achieving the Fast-Track targets would
require an additional 135,000 HIV diagnoses and 232,000
people on treatment by 2020 relative to 2016 (an increase in
around 80% over 2016 treatment numbers; see Figure 2b).
Using unit cost estimates from the South African HIV and TB
Investment Case [28] in combination with the model’s esti-
mates of the programme coverage targets required to reach
the first two stages of the 90-90-90 and 95-95-95 targets,
we broadly estimated total investment requirements of ZAR
6.94 billion (USD 0.51 billion) over the 4 years to 2020, and
ZAR 32.1 billion (USD 2.37 billion) over the 14 years to 2030
(Tables 2 and 3). Taking into account the proportion of the
population living in Johannesburg, our estimates of Johannes-
burg’s investment requirements to 2020 are commensurate
with those provided in the 2017 to 2022 NSP[24]. Around
10% of total investments would be required for testing pro-
grammes and the remainder for funding significant expansions
to treatment and care programmes.
3.3 | The impact of achieving the Fast-Track
targets
If the status quo were maintained across the care and treat-
ment cascade (i.e. if current programmatic coverage were
maintained such that the proportions of those diagnosed, in
care, receiving treatment and virally suppressed remained
constant), we estimate that Johannesburg could expect
303,000 new infections and 96,000 AIDS-related deaths
between 2016 and 2030, such that there would be around
769,000 PLHIV by 2030 (Figure 3; base case). In contrast,
achieving the 2020 and 2030 Fast-Track targets would avert
177,000 infections and 56,500 deaths by 2030 (reductions of
around 58%), leading to a 26% reduction in the number of
PLHIV in 2030 compared to baseline and a 2.2%point reduc-
tion in prevalence compared to baseline (Figure 3). While the
treatment scale-up that would be required in order to meet
the 90-90-90 targets is significant, it is on par with the treat-
ment scale-up that took place over the first half of the decade
(Figure 2b). Furthermore, achieving the 90-90-90 targets by
2020 would mean that 95-95-95 targets were within reach.
3.4 | Scaling up primary prevention programmes
reduces the cost of reaching the Fast-Track targets:
impact of biomedical prevention service scale-up
We considered the impact of implementing the targeted
biomedical prevention services outlined in sub-objective 1.1.2
of South Africa’s National Strategic Plan (NSP) for 2017 to
2022. This sub-objective outlines a comprehensive approach
for the implementation of targeted biomedical prevention ser-
vices, with 5 components related to the provision of HIV
Table 2. Coverage and investment levels required to achieve the first two 90 targets and the first two 95 targets under different
assumptions about prevention programme coverage.
2016 2017 2018 2019 2020
Annual average
2021–2030 Total 2017–2030
Achieving 90% aware by 2020 and 95% aware by 2030
Adult testing rates 51% 58% 65% 72% 80% 80% –
Target population (millions) 3.8 3.9 4.0 4.1 4.2 4.3 59.2
Number of tests required (millions) 1.9 2.3 2.6 3.0 3.4 3.4 45.3
Investment required (ZAR millions) 183 213 245 278 317 183 2,883
Requirements to achieve 90% on treatment by 2020 and 95% by 2030 without scale-up in other prevention programmes
Current prevention programme coverage maintained
Number required on ART (millions) 0.299 0.368 0.419 0.474 0.530 0.568 7.474
Investment required (ZAR millions) 1,161 1,426 1,626 1,838 2,055 2,205 28,999
Requirements to achieve 90% on treatment by 2020 and 95% by 2030 with VMMC scale-up
Number required on ART (millions) 0.299 0.366 0.416 0.468 0.521 0.556 7.331
ART investments required (ZAR millions) 1,160 1,422 1,612 1,814 2,020 2,158 28,445
Requirements to achieve 90% on treatment by 2020 and 95% by 2030 with VMMC and condom distribution scale-up
Number required on ART (millions) 0.299 0.367 0.416 0.468 0.521 0.549 7.265
ART investments required (ZAR millions) 1,160 1,422 1,614 1,816 2,020 2,132 28,188
Requirements to achieve 90% on treatment by 2020 and 95% by 2030 with VMMC and condom distribution scale-up + FSW strategy
Number required on ART (millions) 0.299 0.367 0.416 0.468 0.519 0.542 7.189
ART investments required (ZAR millions) 1,160 1,422 1,614 1,814 2,016 2,103 27,893
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testing and counselling (HTC), 2 related to the voluntary med-
ical male circumcision (VMMC) programme, and a final compo-
nent promising the provision of male and female condoms
(plus compatible lubricant) in all public and private health facil-
ities, in secondary schools, tertiary institutions, non-traditional
community settings[24]. Since the Fast-Track targets subsume
the HTC targets, we do not model this separately here.
Rather, we model the impact of scaling up the VMMC pro-
gramme and the male and female condom distribution
programmes in line with national targets, which aim for 2.5
million medical circumcisions over 2017 to 2020 and the
annual distribution of 850 million male condoms and 40 mil-
lion female condoms. Assuming that the national targets are
proportional to population size, we translate these to targets
for Johannesburg of 220,000 medical circumcisions over
2017–2020, and annual provision of 68 million male condoms
and 3.2 million female condoms. On programme efficacy, we
assume that circumcision reduces the probability of HIV-
Table 3. Summary of the total investments required to achieve the first two 90 targets and the first two 95 targets, as well as the
savings made under different assumptions about prevention programme scale-up and the impact in terms of infections averted.
Current prevention
programme coverage
maintained (base)
VMMC
scale-up
VMMC and condom
distribution scale-up
VMMC and condom
distribution scale-up +
FSW strategy
Investment in ART & HTC to achieve
90/90 & 95/95, 2017–30 (ZAR m)
31,882 31,328 31,071 30,776
Cost of prevention programme
scale-up, 2017–30 (ZAR m)
– 266 1,321 Not estimated
Savings in ART & HTC programmes
relative to base, 2017–30 (ZAR m)
– 554 811 1,106
Net savings relative to base, 2017–30 (ZAR m) – 288 510 Not estimated
Infections averted relative to base, 2017–30 – 4% 8% 14%
(a) (b)
(c) (d)
Figure 3. Key epidemic indicators assuming current programme coverage maintained and Fast-Track targets are met by scaling up HIV diag-
nosis, treatment and viral suppression, with all other programmes maintained at their latest reported coverage levels.
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negative males acquiring infection by 58% [23] and that
reaching the condom distribution targets would result in con-
doms being used in 80% of acts between casual partners
(compared to 50% in 2012; see Table S1 and Figure S2 in
Supplementary Material for calculations).
We calculate that reaching the VMMC target would require
an investment of ZAR 266 million (USD 19.7 million) over
4 years, while reaching the condom distribution targets would
require annual investment of ZAR 94 million (USD 6.9 million)
(see Table S1 in Supplementary Material for calculations). In
combination, attaining these two targets by 2020 and there-
after maintaining them would reduce cumulative new infec-
tions between 2017 and 2030 by a further 9% compared to a
base case scenario in which coverage of these two pro-
grammes is maintained at current levels. This would imply
ZAR 811 million (USD 59.9 million) in savings to the cumula-
tive treatment budget to 2030 (Table 3). Investing in the
VMMC programme in particular is cost saving: we find that
scaling up VMMC alone would deliver a ZAR 554 million
(USD 40.1 million) saving to the overall treatment budget out
to 2030, and thus would deliver modest net savings even
after accounting for the cost of scale-up.
3.5 | Impact of implementing the National Sex
Worker HIV Plan
We consider the impact of the South African National Sex
Worker HIV Plan 2016 to 2019 [25]. In light of the signifi-
cant body of evidence demonstrating the impact of structural
interventions on the health service use and uptake of
biomedical services among sex workers[29,30], we would like
to capture the impact of the structural elements of the pack-
age, notably the Human Rights Package (comprising law
reform, decriminalization, legal literacy and legal service use),
the Social Capital Building Package (comprising community
empowerment, and collectivization), and the Economic
Empowerment Package (comprising skill building, career-path
defining, and participation in cooperatives and education
interventions). Full-scale financing and implementation of
these structural packages in combination with the implemen-
tation of the Health Care package is associated with out-
comes of: [1] 95% condom use in FSW/client commercial
acts in 2020, and [2] provision of PrEP to 3000 HIV-negative
FSWs in 2016, with coverage then extended to all HIV-nega-
tive FSWs. Assuming that the national targets are propor-
tional to population size, we translate the latter target to
mean that 240 HIV-negative FSWs in Johannesburg would
be provided with PrEP in 2016 (4% coverage), scaling up to
4800 by 2020 (80% coverage). If implemented in addition to
the scale-up of HIV diagnosis and treatment programmes
needed to attain the Fast-Track targets and the planned
scale-up to VMMC and condom distribution services, we esti-
mate that implementing the SW strategy would reduce
cumulative new infections between 2016 and 2030 by a fur-
ther 7%, and would mean that the Fast-Track targets would
be attainable with ZAR 295 million (USD 21.9 million) less
required for total treatment investment (Table 3). Unfortu-
nately we are unable to determine cost estimates for the
structural elements of the package due to a lack of cost and
effectiveness data, so we are unable to determine the magni-
tude of savings overall.
4 | DISCUSSION
The results presented in this paper highlight the tremendous
impact that achieving the Fast-Track targets would have on
the HIV epidemic in the City of Johannesburg, while also
demonstrating the still-crucial role that primary prevention
programmes play in both reducing HIV transmission and in
reducing the future financial burden of achieving the Fast-
Track targets. We focused on estimating the investments that
would be required in order to get 90% of people diagnosed
by 2020 and 90% of those diagnosed onto treatment (with
those percentages increasing to 95% by 2030) under different
assumptions around prevention programme scale-up. We also
identified key leakages along the cascade that currently pre-
sent barriers to achieving the Fast-Track targets, with key
problem areas being the rate of linkage to care within
3 months and the rate of viral suppression among those
receiving treatment. The state of the care and treatment cas-
cade in Johannesburg has improved greatly over first half of
this decade, but there is still significant work to be done if the
Fast-Track targets are to be achieved, and these areas should
be particular focal points.
Johannesburg’s Implementation Plan for 2016/17 is a testa-
ment to the health authorities’ commitment to addressing the
programmatic scale-up implied by the Fast-Track targets. HTC
will be promoted in many different ways: through campaigns
in high-transmission areas and among key populations, by
making HTC access more convenient (e.g. alternative opening
times of services, mobile provision) and integrated (e.g. rein-
vigorated provider-initiated counselling and testing, HTC in
clinic waiting areas, improved index testing), through
approaches to diagnose more men (e.g. targeting factories,
transport hubs, tertiary institutions) and by focusing on yield
through continuous monitoring and adjustment of efforts.
Counsellors will be distributed according to need and clinics’
HTC targets, and the electronic ART patient record system
will be expanded to include HTC data. Equally important is
the authorities’ scale-up efforts to link diagnosed HIV cases to
care and treatment (which will help with the estimated need
of putting an additional 232,000 people on treatment by
2020). Given that linkage to care is especially challenging if
HTC is provided at community level, various providers are
tasked with facilitating this process, using the Department of
Health’s ward based teams and civil society organizations.
Adequate supply of HIV drugs and prevention of stock-outs
using the new “Stock Visibility Solution” infrastructure are also
in the plan. In order to support adherence, differentiated care
options are being or have been introduced, including decen-
tralized medicine delivery schemes, adherence clubs, fast
queuing, tracing of those lost to care, and enhanced adher-
ence counselling. This will be supported by improved data sys-
tems to identify patients in need of laboratory monitoring,
drug refill and additional adherence support. In parallel, scale-
up plans are in place for other core HIV prevention services,
including the National Sex Worker HIV plan, plans for
enhanced condom distribution based on evidence of need and
stock management, and increasing involvement of general
practitioners to provide free VMMC services.
We note several limitations to the analyses presented. First,
limitations in data availability and reliability can lead to uncer-
tainty surrounding projected results, and these uncertainties
Stuart RM et al. Journal of the International AIDS Society 2018, 21:e25068
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25068/full | https://doi.org/10.1002/jia2.25068
8
were not quantified. Second, many of the Optima HIV model
parameters (most notably those related to transmission proba-
bilities, disease progression and programme efficacy) were
sourced from clinical and research studies, and may differ
from the values that would be observed in Johannesburg.
Third, our estimates of the impact of biomedical prevention
service scale-up assume that the planned investments in con-
dom and VMMC scale-up would be met with increased con-
dom use and increase rates of medical circumcision.
Particularly with respect to condom usage, this may be an
optimistic assumption as behaviour changes of this type can
be difficult to attain in practice. Fourth, our analysis of the
costs assumes that all programmes continue to operate at cur-
rent levels of efficiency, and does not consider the effect of
potential efficiency gains. There are various studies that have
highlighted the potential for efficiency gains in the implemen-
tation of prevention programmes [31], including specific stud-
ies on HTC [32], VMMC [33], condom distribution programme
[34], and sex worker programme [35] efficiency in various con-
texts in sub-Saharan Africa. More functional integration of HIV
services, as is currently happening in South Africa within the
Integrated Chronic Disease Management and Chronic Treat-
ment Adherence guidelines, creates economies of scope and
may also improve the client experience. Technical efficiency
gains, in areas where large volumes of patients are to be
served such as Johannesburg, are feasible to gain economies
of scale and reduce unit costs (e.g. South Africa’s task shifting
to lower level health cadres, price reductions of drugs and
diagnostic tests). Also, efficiency gains may be made through
better targeting of programmes, the use of different service
delivery modalities, or cutting back on indirect programme
costs. It is therefore worth investigating whether such effi-
ciency gains may be made here. However, while there may be
further cost-savings possible in the Johannesburg HIV pro-
gramme in the future, some are likely offset by the effort
required to identify additional and harder-to-reach cases and
get them linked to HIV care and virally suppressed. HIV testing
yield illustrates this challenge of case identification well: in
South Africa, six people needed to be tested in 2005 to find
one new HIV case in 2005; in 2015 this increased to testing
18 people [36]. Another factor potentially offsetting the savings
gained through efficiencies is the need to switch more ART cli-
ents to second line HIV treatment, which remains more costly.
The importance to Johannesburg of meeting the Fast-Track
targets–thereby averting an estimated 177,000 infections and
56,500 deaths by 2030 and reducing the number of people
living with HIV by a third – cannot be overemphasized. Ensur-
ing scale and quality of the HIV treatment programme is vital
for the city’s economic prosperity and for South Africa as a
whole. Johannesburg’s commitment towards the Fast-Track
targets echoes the national dedication to achieving the targets
and ending AIDS by 2030. “Universal test and treat” (UTT)
became national policy in September 2016, with accelerated
efforts being made for HIV clinic decongestion, down-referral
of HIV clients, decentralization of services and community-
based monitoring to facilitate UTT. Substantial investments
continue to be made throughout South Africa to support HIV
testing, linkage to care, pre-ART care, and treatment initiation,
maintenance and adherence. The focus on diagnosing HIV-
positive individuals over recent years has paid off with large
increases in the proportion of people aware of their status,
and South Africa has also been successful in initiating large
numbers of people onto ART. However, significant work
remains to be done on a national scale, particularly with
respect to improving retention and adherence rates.
Enhanced analysis of the HIV care cascade is crucial for
guiding the large investments that will be required to achieve
the Fast-Track targets. In particular, translating broad political
targets into actionable stratagems requires detailed knowl-
edge of the current status of the care and treatment cascade,
as well as an understanding of the likely future trajectories of
the HIV epidemic. There is scope for mathematical models to
help with the latter, and for improved data collection and anal-
ysis to help with the former. Conducting analyses at a city
level means that goals can be mapped against operational
budgets, and translated into targets for the clinical and service
provision networks. Such analyses would be best conducted
within a broader national context, in order to ensure coher-
ence across different jurisdictional levels. Our modelling
methodology would be well-suited for many other cities, espe-
cially those who have committed to achieving the Fast-Track
targets, and could be used to answer similar questions about
resource needs and impact in a range of settings.
5 | CONCLUSIONS
Enhanced analysis of the HIV care cascade is crucial for guiding
the large investments that will be required in order to achieve
the goal of ending AIDS by 2030. By providing annual denomina-
tors of people living with HIV and requiring services of HIV test-
ing, linkage, treatment initiation and treatment maintenance, this
analysis hopes to inform target setting for the Fast-Track
response and as a baseline for UTT. For Johannesburg, getting
HIV service delivery right – guided by ruthless data tracking and
enhanced analysis – in an era of prolonged and increasing urban-
ization and rapidly growing ART programme costs is vital both for
the individuals who live there, and for the economy as a whole.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article:
Figure S1. shows the model estimates of HIV prevalence in
each sub-population compared to available data.
Table S1. Calculations to determine the cost of scaling up the
VMMC and condom distribution programmes in Johannesburg
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